Biomarkers in TAA-the holy grail

Progress in Cardiovascular Diseases

Volumn 56, Issue 1, 2013, Pages 109-115

  van Bogerijen, Guido H W ^a   Tolenaar, Jip L ^a   Grassi, Viviana ^a   Lomazzi, Chiara ^a   Segreti, Sara ^a   Rampoldi, Vincenzo ^a   Elefteriades, John A ^b   Trimarchi, Santi ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Biomarkers; TAA; Thoracic aortic aneurysm

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CARBONYL DERIVATIVE; COLLAGEN; CYTOKINE; D DIMER; ELASTIN; ENDOTHELIN; FIBRINOGEN; FIBULIN; FILAMIN; GAMMA INTERFERON; HOMOCYSTEINE; LIPOPROTEIN; LOSARTAN; MATRIX METALLOPROTEINASE; OSTEOPONTIN; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR; PROTHROMBIN; SMAD PROTEIN; THROMBOSPONDIN 2; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE PLASMINOGEN ACTIVATOR; TRANSFORMING GROWTH FACTOR BETA;

ABDOMINAL AORTA ANEURYSM; AORTA ATHEROSCLEROSIS; ARTICLE; ENDOVASCULAR ANEURYSM REPAIR; GENE EXPRESSION; GENE MUTATION; HEMOSTASIS; HUMAN; MARFAN SYNDROME; OXIDATIVE STRESS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN METABOLISM; TELOMERE; THORACIC AORTA ANEURYSM;

AAA; ABDOMINAL AORTIC ANEURYSM; BIOMARKERS; C-REACTIVE PROTEIN; COMPUTED TOMOGRAPHY; CRP; CT; ECM; ENDOTHELIN; ET; EXTRACELLULAR MATRIX; MAGNETIC RESONANCE IMAGING; MATRIX METALLOPROTEINASE; MMP; MRI; N-TERMINAL PRO-BRAIN NATRIURETIC PEPTIDE; NT-PROBNP; SMC; SMOOTH MUSCLE CELLS; TAA; TEVAR; TGF-Β; THORACIC AORTIC ANEURYSM; THORACIC ENDOVASCULAR AORTIC REPAIR; TIMP; TISSUE INHIBITORS OF MATRIX METALLOPROTEINASES; TRANSFORMING GROWTH FACTOR Β;

AORTIC ANEURYSM, THORACIC; BIOLOGICAL MARKERS; GENE EXPRESSION PROFILING; GENETIC MARKERS; GENETIC TESTING; HUMANS; MASS SCREENING; PREDICTIVE VALUE OF TESTS; PROGNOSIS;

EID: 84883055594     PISSN: 00330620     EISSN: 18731740     Source Type: Journal    
DOI: 10.1016/j.pcad.2013.05.004     Document Type: Article

References (67)

1. Booher A.M., Eagle K.A. Diagnosis and management issues in thoracic aortic aneurysm. Am Heart J 2011, 162:38-46.
2. Hovsepian D.M., Ziporin S.J., Sakurai M.K., Lee J.K., Curci J.A., Thompson R.W. Elevated plasma levels of matrix metalloproteinase-9 in patients with abdominal aortic aneurysms: a circulating marker of degenerative aneurysm disease. J Vasc Interv Radiol 2000, 11:1345-1352.
3. Bick R.L. Disseminated intravascular coagulation. Objective laboratory diagnostic criteria and guidelines for management. Clin Lab Med 1994, 14:729-768.
4. Costantini V., Zacharski L.R. Fibrin and cancer. Thromb Haemost 1993, 69:406-414.
5. Goldhaber S.Z., Simons G.R., Elliott C.G., et al. Quantitative plasma d-dimer levels among patients undergoing pulmonary angiography for suspected pulmonary embolism. JAMA 1993, 270:2819-2822.
6. Suzuki T., Distante A., Zizza A., et al. Diagnosis of acute aortic dissection by d-dimer: the International Registry of Acute Aortic Dissection Substudy on Biomarkers (IRAD-Bio) experience. Circulation 2009, 119:2702-2707.
7. Serino F., Abeni D., Galvagni E., et al. Noninvasive diagnosis of incomplete endovascular aneurysm repair: d-dimer assay to detect type I endoleaks and nonshrinking aneurysms. J Endovasc Ther 2002, 9:90-97.
8. Urbonavicius S., Urbonaviciene G., Honore B., Henneberg E.W., Vorum H., Lindholt J.S. Potential circulating biomarkers for abdominal aortic aneurysm expansion and rupture-a systematic review. Eur J Vasc Endovasc Surg 2008, 36:273-280.
9. Knox J.B., Sukhova G.K., Whittemore A.D., Libby P. Evidence for altered balance between matrix metalloproteinases and their inhibitors in human aortic diseases. Circulation 1997, 95:205-212.
10. Vine N., Powell J.T. Metalloproteinases in degenerative aortic disease. Clin Sci (Lond) 1991, 81:233-239.
11. Koullias G.J., Ravichandran P., Korkolis D.P., Rimm D.L., Elefteriades J.A. Increased tissue microarray matrix metalloproteinase expression favors proteolysis in thoracic aortic aneurysms and dissections. Ann Thorac Surg 2004, 78:2106-2110.
12. Sangiorgi G., D'Averio R., Mauriello A., et al. Plasma levels of metalloproteinases-3 and -9 as markers of successful abdominal aortic aneurysm exclusion after endovascular graft treatment. Circulation 2001, 104(12 Suppl 1):I288-I295.
13. Monaco M., Stassano P., Di T.L., Iannelli G. Response of plasma matrix metalloproteinases and tissue inhibitor of metalloproteinases to stent-graft surgery for descending thoracic aortic aneurysms. J Thorac Cardiovasc Surg 2007, 134:925-931.
14. Ikonomidis J.S., Jones J.A., Barbour J.R., et al. Expression of matrix metalloproteinases and endogenous inhibitors within ascending aortic aneurysms of patients with Marfan syndrome. Circulation 2006, 114(1 Suppl):I365-I370.
15. Schmoker J.D., McPartland K.J., Fellinger E.K., et al. Matrix metalloproteinase and tissue inhibitor expression in atherosclerotic and nonatherosclerotic thoracic aortic aneurysms. J Thorac Cardiovasc Surg 2007, 133:155-161.
16. Sinha I., Bethi S., Cronin P., et al. A biologic basis for asymmetric growth in descending thoracic aortic aneurysms: a role for matrix metalloproteinase 9 and 2. J Vasc Surg 2006, 43:342-348.
17. Bonnier F., Rubin S., Debelle L., et al. FTIR protein secondary structure analysis of human ascending aortic tissues. J Biophotonics 2008, 1:204-214.
18. Iliopoulos D.C., Kritharis E.P., Giagini A.T., Papadodima S.A., Sokolis D.P. Ascending thoracic aortic aneurysms are associated with compositional remodeling and vessel stiffening but not weakening in age-matched subjects. J Thorac Cardiovasc Surg 2009, 137:101-109.
19. Satta J., Juvonen T., Haukipuro K., Juvonen M., Kairaluoma M.I. Increased turnover of collagen in abdominal aortic aneurysms, demonstrated by measuring the concentration of the aminoterminal propeptide of type III procollagen in peripheral and aortal blood samples. J Vasc Surg 1995, 22:155-160.
20. Wilson K.A., Lindholt J.S., Hoskins P.R., Heickendorff L., Vammen S., Bradbury A.W. The relationship between abdominal aortic aneurysm distensibility and serum markers of elastin and collagen metabolism. Eur J Vasc Endovasc Surg 2001, 21:175-178.
21. Davis V.A., Persidskaia R.N., Baca-Regen L.M., Fiotti N., Halloran B.G., Baxter B.T. Cytokine pattern in aneurysmal and occlusive disease of the aorta. J Surg Res 2001, 101:152-156.
22. Jones K.G., Brull D.J., Brown L.C., et al. Interleukin-6 (IL-6) and the prognosis of abdominal aortic aneurysms. Circulation 2001, 103:2260-2265.
23. Schonbeck U., Sukhova G.K., Gerdes N., Libby P. T(H)2 predominant immune responses prevail in human abdominal aortic aneurysm. Am J Pathol 2002, 161:499-506.
24. Walton L.J., Franklin I.J., Bayston T., et al. Inhibition of prostaglandin E2 synthesis in abdominal aortic aneurysms: implications for smooth muscle cell viability, inflammatory processes, and the expansion of abdominal aortic aneurysms. Circulation 1999, 100:48-54.
25. Wang Y., Barbacioru C.C., Shiffman D., et al. Gene expression signature in peripheral blood detects thoracic aortic aneurysm. PLoS One 2007, 2:e1050.
26. Dawson J., Cockerill G.W., Choke E., Belli A.M., Loftus I., Thompson M.M. Aortic aneurysms secrete interleukin-6 into the circulation. J Vasc Surg 2007, 45:350-356.
27. Henderson E.L., Geng Y.J., Sukhova G.K., Whittemore A.D., Knox J., Libby P. Death of smooth muscle cells and expression of mediators of apoptosis by T lymphocytes in human abdominal aortic aneurysms. Circulation 1999, 99:96-104.
28. Middleton R.K., Lloyd G.M., Bown M.J., Cooper N.J., London N.J., Sayers R.D. The pro-inflammatory and chemotactic cytokine microenvironment of the abdominal aortic aneurysm wall: a protein array study. J Vasc Surg 2007, 45:574-580.
29. Shimizu K., Shichiri M., Libby P., Lee R.T., Mitchell R.N. Th2-predominant inflammation and blockade of IFN-gamma signaling induce aneurysms in allografted aortas. J Clin Invest 2004, 114:300-308.
30. Shimizu K., Mitchell R.N., Libby P. Inflammation and cellular immune responses in abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol 2006, 26:987-994.
31. Guo D., Hasham S., Kuang S.Q., et al. Familial thoracic aortic aneurysms and dissections: genetic heterogeneity with a major locus mapping to 5q13-14. Circulation 2001, 103:2461-2468.
32. Kakko S., Raisanen T., Tamminen M., et al. Candidate locus analysis of familial ascending aortic aneurysms and dissections confirms the linkage to the chromosome 5q13-14 in Finnish families. J Thorac Cardiovasc Surg 2003, 126:106-113.
33. Trimarchi S., Sangiorgi G., Sang X., et al. In search of blood tests for thoracic aortic diseases. Ann Thorac Surg 2010, 90:1735-1742.
34. Domanovits H., Schillinger M., Mullner M., et al. Acute phase reactants in patients with abdominal aortic aneurysm. Atherosclerosis 2002, 163:297-302.
35. Lagrand W.K., Visser C.A., Hermens W.T., et al. C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon?. Circulation 1999, 100:96-102.
36. Vainas T., Lubbers T., Stassen F.R., et al. Serum C-reactive protein level is associated with abdominal aortic aneurysm size and may be produced by aneurysmal tissue. Circulation 2003, 107:1103-1105.
37. Yuan S.M., Shi Y.H., Wang J.J., Lu F.Q., Gao S. Elevated plasma d-dimer and hypersensitive C-reactive protein levels may indicate aortic disorders. Rev Bras Cir Cardiovasc 2011, 26:573-581.
38. Koenig W., Sund M., Ernst E., Mraz W., Hombach V., Keil U. Association between rheology and components of lipoproteins in human blood. Results from the MONICA project. Circulation 1992, 85:2197-2204.
39. Lindholt J.S., Jorgensen B., Shi G.P., Henneberg E.W. Relationships between activators and inhibitors of plasminogen, and the progression of small abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 2003, 25:546-551.
40. Schillinger M., Domanovits H., Ignatescu M., et al. Lipoprotein (a) in patients with aortic aneurysmal disease. J Vasc Surg 2002, 36:25-30.
41. Lindholt J.S., Jorgensen B., Fasting H., Henneberg E.W. Plasma levels of plasmin-antiplasmin-complexes are predictive for small abdominal aortic aneurysms expanding to operation-recommendable sizes. J Vasc Surg 2001, 34:611-615.
42. Adam D.J., Haggart P.C., Ludlam C.A., Bradbury A.W. Hemostatic markers before operation in patients with acutely symptomatic nonruptured and ruptured infrarenal abdominal aortic aneurysm. J Vasc Surg 2002, 35:661-665.
43. Cannan C.R., Burnett J.C., Brandt R.R., Lerman A. Endothelin at pathophysiological concentrations mediates coronary vasoconstriction via the endothelin-A receptor. Circulation 1995, 92:3312-3317.
44. Treska V., Wenham P.W., Valenta J., Topolcan O., Pecen L. Plasma endothelin levels in patients with abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 1999, 17:424-428.
45. Konecky N., Malinow M.R., Tunick P.A., et al. Correlation between plasma homocyst(e)ine and aortic atherosclerosis. Am Heart J 1997, 133:534-540.
46. Coull B.M., Malinow M.R., Beamer N., Sexton G., Nordt F., de G.P. Elevated plasma homocyst(e)ine concentration as a possible independent risk factor for stroke. Stroke 1990, 21:572-576.
47. Graham I.M., Daly L.E., Refsum H.M., et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA 1997, 277:1775-1781.
48. Loeys B.L., Schwarze U., Holm T., et al. Aneurysm syndromes caused by mutations in the TGF-beta receptor. N Engl J Med 2006, 355:788-798.
49. Matt P., Habashi J., Carrel T., Cameron D.E., Van Eyk J.E., Dietz H.C. Recent advances in understanding Marfan syndrome: should we now treat surgical patients with Losartan?. J Thorac Cardiovasc Surg 2008, 135:389-394.
50. Forteza A., Evangelista A., Sanchez V., et al. Study of the efficacy and safety of Losartan versus atenolol for aortic dilation in patients with Marfan syndrome. Rev Esp Cardiol 2011, 64:492-498.
51. Balistreri C.R., Pisano C., Merlo D., et al. Is the mean blood leukocyte telomere length a predictor for sporadic thoracic aortic aneurysm? Data from a preliminary study. Rejuvenation Res 2012, 15:170-173.
52. Hucthagowder V., Sausgruber N., Kim K.H., Angle B., Marmorstein L.Y., Urban Z. Fibulin-4: a novel gene for an autosomal recessive cutis laxa syndrome. Am J Hum Genet 2006, 78:1075-1080.
53. Loeys B., Van M.L., Mortier G., et al. Homozygosity for a missense mutation in fibulin-5 (FBLN5) results in a severe form of cutis laxa. Hum Mol Genet 2002, 11:2113-2118.
54. Al-Hassnan Z.N., Almesned A.R., Tulbah S., et al. Recessively inherited severe aortic aneurysm caused by mutated EFEMP2. Am J Cardiol 2012, 109:1677-1680.
55. Kato K., Oguri M., Kato N., et al. Assessment of genetic risk factors for thoracic aortic aneurysm in hypertensive patients. Am J Hypertens 2008, 21:1023-1027.
56. Sheen V.L., Jansen A., Chen M.H., et al. Filamin A mutations cause periventricular heterotopia with Ehlers-Danlos syndrome. Neurology 2005, 64:254-262.
57. Pilop C., Aregger F., Gorman R.C., et al. Proteomic analysis in aortic media of patients with Marfan syndrome reveals increased activity of calpain 2 in aortic aneurysms. Circulation 2009, 120:983-991.
58. van de Laar I.M., Oldenburg R.A., Pals G., et al. Mutations in SMAD3 cause a syndromic form of aortic aneurysms and dissections with early-onset osteoarthritis. Nat Genet 2011, 43:121-126.
59. Regalado E.S., Guo D.C., Villamizar C., et al. Exome sequencing identifies SMAD3 mutations as a cause of familial thoracic aortic aneurysm and dissection with intracranial and other arterial aneurysms. Circ Res 2011, 109:680-686.
60. van de Laar I.M., van der Linde D., Oei E.H., et al. Phenotypic spectrum of the SMAD3-related aneurysms-osteoarthritis syndrome. J Med Genet 2012, 49:47-57.
61. Fiorillo C., Becatti M., Attanasio M., et al. Evidence for oxidative stress in plasma of patients with Marfan syndrome. Int J Cardiol 2010, 145:544-546.
62. Ejiri J., Inoue N., Tsukube T., et al. Oxidative stress in the pathogenesis of thoracic aortic aneurysm: protective role of statin and angiotensin II type 1 receptor blocker. Cardiovasc Res 2003, 59:988-996.
63. Gallo A., Saad A., Ali R., Dardik A., Tellides G., Geirsson A. Circulating interferon-gamma-inducible Cys-X-Cys chemokine receptor 3 ligands are elevated in humans with aortic aneurysms and Cys-X-Cys chemokine receptor 3 is necessary for aneurysm formation in mice. J Thorac Cardiovasc Surg 2012, 143:704-710.
64. Zhang L., Liao M.F., Tian L., et al. Overexpression of interleukin-1 beta and interferon-gamma in type I thoracic aortic dissections and ascending thoracic aortic aneurysms: possible correlation with matrix metalloproteinase-9 expression and apoptosis of aortic media cells. Eur J Cardiothorac Surg 2011, 40:17-22.
65. Huusko T., Salonurmi T., Taskinen P., et al. Elevated messenger RNA expression and plasma protein levels of osteopontin and matrix metalloproteinase types 2 and 9 in patients with ascending aortic aneurysms. J Thorac Cardiovasc Surg 2012.
66. Lesauskaite V., Tanganelli P., Sassi C., et al. Smooth muscle cells of the media in the dilatative pathology of ascending thoracic aorta: morphology, immunoreactivity for osteopontin, matrix metalloproteinases, and their inhibitors. Hum Pathol 2001, 32:1003-1011.
67. Sbarouni E., Georgiadou P., Marathias A., Geroulanos S., Kremastinos D.T. d-Dimer and BNP levels in acute aortic dissection. Int J Cardiol 2007, 122:170-172.